GSK plc (NYSE: GSK) execs add ADS via dividend plans on Aug. 14

Rhea-AI Filing Summary

GSK plc (GSK) reported several acquisitions of American Depositary Shares involving senior personnel through dividend reinvestment on plan accounts. Dr Hal Barron, a non-executive director, acquired 2,279.563 notional ADS in an Executive Supplemental Savings Plan and 73 ADS in a 401(k) plan. James Ford, SVP and Group General Counsel, acquired 53.890 notional ADS, and Maya Martinez-Davis, President, acquired 82.133 notional ADS. All transactions took place on 14 August 2026 on the New York Stock Exchange at a price of $49.5200 per ADS and resulted from the reinvestment of dividends in GSK-sponsored plans.

Key Figures

ADS transaction price: $49.5200 per ADS Notional ADS acquired by Dr Hal Barron (Supplemental Plan): 2,279.563 ADS ADS acquired by Dr Hal Barron (401(k) plan): 73 ADS +3 more

6 metrics

ADS transaction price $49.5200 per ADS Price for all reported ADS and notional ADS acquisitions on 14 August 2026

Notional ADS acquired by Dr Hal Barron (Supplemental Plan) 2,279.563 ADS Acquisition within GSK Executive Supplemental Savings Plan via dividend reinvestment

ADS acquired by Dr Hal Barron (401(k) plan) 73 ADS Acquisition within GSK 401(k) plan via dividend reinvestment

Notional ADS acquired by James Ford 53.890 ADS Acquisition within GSK Executive Supplemental Savings Plan via dividend reinvestment

Notional ADS acquired by Maya Martinez-Davis 82.133 ADS Acquisition within GSK Executive Supplemental Savings Plan via dividend reinvestment

Transaction date 14 August 2026 Date of all reported ADS and notional ADS acquisitions

Key Terms

Person Discharging Managerial Responsibilities, American Depositary Shares, Executive Supplemental Savings Plan, reinvestment of dividends, +1 more

5 terms

Person Discharging Managerial Responsibilities regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS')"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Executive Supplemental Savings Plan financial

"Acquisition of notional ADS within GSK Executive Supplemental Savings Plan account"

reinvestment of dividends financial

"Acquisition of notional ADS ... following the reinvestment of dividends"

401(k) plan financial

"Acquisition of ADS within Dr Barron's GSK 401(k) plan account"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

FAQ

What insider share transactions did GSK (GSK) disclose in this Form 6-K?

GSK disclosed ADS acquisitions by three senior personnel through dividend reinvestment in company plans. Dr Hal Barron, James Ford, and Maya Martinez-Davis each acquired notional ADS or ADS on 14 August 2026 at $49.5200 per ADS.

How many GSK (GSK) ADS did Dr Hal Barron acquire through dividend reinvestment?

Dr Hal Barron acquired 2,279.563 notional ADS in an Executive Supplemental Savings Plan and 73 ADS in a 401(k) plan. Both transactions occurred on 14 August 2026 at a price of $49.5200 per ADS on the NYSE.

What transactions did James Ford report involving GSK (GSK) ADS?

James Ford, SVP and Group General Counsel, acquired 53.890 notional ADS of GSK through an Executive Supplemental Savings Plan. The acquisition resulted from reinvestment of dividends on 14 August 2026 at $49.5200 per ADS on the NYSE.

What GSK (GSK) ADS acquisition did Maya Martinez-Davis report?

Maya Martinez-Davis, President, acquired 82.133 notional ADS through the company’s Executive Supplemental Savings Plan. This acquisition also came from dividend reinvestment on 14 August 2026 at a price of $49.5200 per ADS on the NYSE.

Were GSK (GSK) insiders buying or selling ADS in these August 2026 transactions?

The reported transactions were acquisitions of ADS and not sales. All acquisitions occurred via reinvestment of dividends into notional ADS or ADS within GSK-sponsored retirement and savings plans on 14 August 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/18/2026 - 10:35 AM Accepted by SEC EDGAR 08/18/2026 - 10:34 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.5200	2,279.563
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-08-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.5200	53.890
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-08-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.5200	82.133
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-08-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.5200	73
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-08-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 18, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc